Paid Clinical Trials in Fountain Valley, CA

As of June 2026, 103 paid clinical trials are recruiting in Fountain Valley, California. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.

Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

103 clinical trials

↓ Download CSV

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

for Hidradenitis Suppurativa

Drug: Ruxolitinib

67 locations incl. Birmingham

Sponsor: Incyte Corporation

Sex: All·Age: 12+

Code: NCT06958211·Phase 3·Recruiting

Apply to this trial

A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.

for Chikungunya Virus

8 locations incl. Fountain Valley

Sponsor: Bavarian Nordic

Sex: All·Age: 1 - 11·Accepts healthy volunteers

Code: NCT07003984·Phase 3·Recruiting

Apply to this trial

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

for Cardiovascular Disease

315 locations incl. Athens

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07000357·Phase 3·Recruiting

Apply to this trial

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

for Obesity

Drug: Retatrutide

25 locations incl. Chandler

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07035093·Phase 3·Recruiting

Apply to this trial

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

for Atopic Dermatitis

22 locations incl. Birmingham

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT06947993·Phase 2·Recruiting

Apply to this trial

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

for Atopic Dermatitis

22 locations incl. Fountain Valley

Sponsor: Apogee Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07003425·Phase 2·Recruiting

Apply to this trial

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

for Psoriasis

Drug: Tirzepatide

40 locations incl. Phoenix

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06857942·Phase 4·Recruiting

Apply to this trial

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

for Psoriatic Arthritis

Drug: Zasocitinib

54 locations incl. Chandler

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT06671483·Phase 3·Recruiting

Apply to this trial

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

for Hidradenitis Suppurativa (HS)

Drug: Povorcitinib

108 locations incl. Birmingham

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT06855498·Phase 3·Recruiting

Apply to this trial

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

for Chemotherapy Induced Neuropathic Pain

25 locations incl. Sheffield

Sponsor: Dogwood Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT06848348·Phase 2·Recruiting

Apply to this trial

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

for Obesity and Overweight

Drug: Tirzepatide

20 locations incl. Bessemer

Sponsor: Gan and Lee Pharmaceuticals, USA

Sex: All·Age: 18 - 75

Code: NCT06737042·Phase 2·Not Yet Recruiting

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

for mCRPC (Metastatic Castration-resistant Prostate Cancer)

18 locations incl. Fountain Valley

Sponsor: Pathos AI, Inc.

Sex: Male·Age: 18+

Code: NCT06785636·Phase 1, Phase 2·Recruiting

Apply to this trial

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

for Parenteral Nutrition Associated Liver Disease (PNALD)

10 locations incl. Fountain Valley

Sponsor: Fresenius Kabi

Sex: All·Age: 1 Day - 17

Code: NCT06274788·Recruiting

Apply to this trial

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

for Hormone Receptor Positive HER-2 Negative Breast Cancer

35 locations incl. Birmingham

Sponsor: Puma Biotechnology, Inc.

Sex: All·Age: 18+

Code: NCT06369285·Phase 2·Recruiting

Apply to this trial

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

for Metabolic Dysfunction Associated Steatohepatitis

Drug: Survodutide

125 locations incl. Peoria

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06632457·Phase 3·Recruiting

Apply to this trial

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

for Metastatic Castration-Resistant Prostate Cancer

Drug: Mevrometostat

44 locations incl. Chandler

Sponsor: Pfizer

Sex: Male·Age: 18+

Code: NCT06629779·Phase 3·Recruiting

Apply to this trial

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

for Metastatic Non-small Cell Lung Cancer

Drug: Osimertinib

34 locations incl. Fayetteville

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT06417814·Phase 3·Recruiting

Apply to this trial

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

for Metabolic Dysfunction Associated Steatohepatitis (MASH)

Drug: Survodutide

165 locations incl. Birmingham

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06632444·Phase 3·Recruiting

Apply to this trial

SuperSaturated Oxygen Comprehensive Observational Registry

for STEMI - ST Elevation Myocardial Infarction

25 locations incl. Fountain Valley

Sponsor: TherOx

Sex: All·Age: 18 - 80

Code: NCT06438315·Recruiting

Apply to this trial

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

for Atopic Dermatitis

6 locations incl. Fountain Valley

Sponsor: Oneness Biotech Co., Ltd.

Sex: All·Age: 18 - 65

Code: NCT06397911·Phase 2·Recruiting

Apply to this trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

for Advanced Breast Cancer

Drug: Camizestrant

54 locations incl. Gilbert

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06380751·Phase 3·Recruiting

Apply to this trial

Galleri® in the Medicare Population.

for Cancer

61 locations incl. Fort Smith

Sponsor: GRAIL, Inc.

Sex: All·Age: 50+·Accepts healthy volunteers

Code: NCT05673018·Recruiting

Apply to this trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

for Solid Tumors

18 locations incl. Birmingham

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT06431594·Phase 1·Recruiting

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

for Moderate to Severe Plaque Psoriasis

Drug: Bimekizumab

9 locations incl. Fountain Valley

Sponsor: UCB Biopharma SRL

Sex: All·Age: 6 - 17

Code: NCT06425549·Phase 3·Recruiting

Apply to this trial

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

for Triple-Negative Breast Cancer

88 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06393374·Phase 3·Recruiting

Apply to this trial

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

for Diabetes Mellitus, Type 1

60 locations incl. Scottsdale

Sponsor: vTv Therapeutics

Sex: All·Age: 18+

Code: NCT06334133·Phase 3·Recruiting

Apply to this trial

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

for Atopic Dermatitis

Drug: Upadacitinib

83 locations incl. Birmingham

Sponsor: AbbVie

Sex: All·Age: 18 - 63

Code: NCT06389136·Phase 3·Recruiting

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

for Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

135 locations incl. Birmingham

Sponsor: 89bio, Inc.

Sex: All·Age: 18 - 75

Code: NCT06419374·Phase 3·Recruiting

Apply to this trial

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

Drug: Osimertinib

36 locations incl. Fountain Valley

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06350097·Phase 3·Recruiting

Apply to this trial

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

for Non-Small Cell Lung Cancer

Drug: Rilvegostomig

63 locations incl. Anchorage

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06357533·Phase 3·Recruiting

Apply to this trial

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

for Advanced Solid Tumor

16 locations incl. Fountain Valley

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT05932862·Phase 1·Recruiting

Apply to this trial

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

141 locations incl. Birmingham

Sponsor: 89bio, Inc.

Sex: All·Age: 18 - 80

Code: NCT06318169·Phase 3·Recruiting

Apply to this trial

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

for Locally Advanced Head and Neck Squamous Cell Carcinoma

70 locations incl. Birmingham

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT06129864·Phase 3·Recruiting

Apply to this trial

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

for Breast Cancer

79 locations incl. Phoenix

Sponsor: BriaCell Therapeutics Corporation

Sex: All·Age: 18+

Code: NCT06072612·Phase 3·Recruiting

Apply to this trial

The Fourth Left Atrial Appendage Occlusion Study

for Atrial Fibrillation

51 locations incl. Birmingham

Sponsor: Hamilton Health Sciences Corporation

Sex: All·Age: 18+

Code: NCT05963698·Recruiting

Apply to this trial

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

for Breast Cancer

Drug: Palazestrant

47 locations incl. Tucson

Sponsor: Olema Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT06016738·Phase 3·Recruiting

Apply to this trial

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

for Alopecia Areata

Drug: Upadacitinib

75 locations incl. Birmingham

Sponsor: AbbVie

Sex: All·Age: 12 - 63

Code: NCT06012240·Phase 3·Recruiting

Apply to this trial

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

for Breast Cancer, Early Breast Cancer

Drug: Camizestrant

148 locations incl. Dothan

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT05952557·Phase 3·Recruiting

Apply to this trial

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

for Breast Cancer, Early Breast Cancer

Drug: Camizestrant

129 locations incl. Birmingham

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT05774951·Phase 3·Recruiting

Apply to this trial

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

for Atopic Dermatitis

21 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: All·Age: 6 Months - 18

Code: NCT05735483·Phase 3·Enrolling By Invitation